Quick Answer
GYRE THERAPEUTICS, INC. reported Operating Income of $11.49 million for fiscal year 2025.
GYRE THERAPEUTICS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $11.49M | -28.9% |
| 2024 | $16.16M | +124.0% |
| 2023 | -$67.23M | -830.5% |
| 2022 | $9.20M | +110.5% |
| 2021 | -$87.89M | -53.2% |
| 2020 | -$57.37M | -0.2% |
| 2019 | -$57.28M | -69.3% |
| 2018 | -$33.82M | -55.0% |
| 2017 | -$21.82M | -6.9% |
| 2016 | -$20.42M | -47.9% |
| 2015 | -$13.80M | -83.8% |
| 2014 | -$7.51M | +25.8% |
| 2013 | -$10.12M | -24.4% |
| 2012 | -$8.14M | +16.5% |
| 2011 | -$9.74M | -174.3% |
| 2010 | $13.12M | +132.5% |
| 2009 | -$40.33M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.92M | +63.6% | +219.0% |
| June 30, 2025 | $2.17M | -32.0% | -4.5% |
| March 31, 2025 | $2.27M | -71.8% | -46.3% |
| September 30, 2024 | $4.23M | -66.8% | +32.5% |
| June 30, 2024 | $3.19M | -35.8% | -60.4% |
| March 31, 2024 | $8.07M | +21.1% | -36.8% |
| September 30, 2023 | $12.76M | +347.1% | +156.6% |
| June 30, 2023 | $4.97M | -90.3% | -25.4% |
- GYRE THERAPEUTICS, INC. showed a decrease of -28.9% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, GYRE THERAPEUTICS, INC.’s operating income has grown by 128.5% (from -$40.33 million to $11.49 million).
- The most recent figure is from GYRE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: